Immutep Partners with Merck for Efti Combination Trials
Ticker: PRRUF · Form: 6-K · Filed: Jul 23, 2024 · CIK: 1506184
| Field | Detail |
|---|---|
| Company | Immutep Ltd (PRRUF) |
| Form Type | 6-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: partnership, clinical-trials, drug-development
Related Tickers: MRK
TL;DR
Immutep teams up with Merck for KEYTRUDA + efti trials, boosting efti's development.
AI Summary
Immutep Ltd. announced on July 22, 2024, that it has entered into a clinical supply agreement with Merck & Co. for its lead product candidate, eftilagimod alpha (efti). Under the agreement, Merck will supply its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for use in combination with efti in ongoing and future clinical trials. This collaboration aims to further evaluate the potential of combining these therapies.
Why It Matters
This collaboration with a major pharmaceutical company like Merck could significantly accelerate the development and potential market approval of Immutep's lead drug candidate, eftilagimod alpha, by leveraging Merck's established therapy.
Risk Assessment
Risk Level: medium — While a partnership with Merck is positive, the success of the combined therapy is still dependent on clinical trial outcomes and regulatory approvals.
Key Players & Entities
- Immutep Ltd. (company) — Registrant
- Merck & Co. (company) — Partner in clinical supply agreement
- eftilagimod alpha (drug) — Immutep's lead product candidate
- KEYTRUDA (drug) — Merck's anti-PD-1 therapy
- July 22, 2024 (date) — Date of announcement
FAQ
What is the nature of the agreement between Immutep and Merck & Co.?
Immutep Ltd. entered into a clinical supply agreement with Merck & Co. for its lead product candidate, eftilagimod alpha (efti). Merck will supply its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for use in combination with efti in clinical trials.
What is Immutep's lead product candidate?
Immutep's lead product candidate is eftilagimod alpha (efti).
What therapy will Merck & Co. supply for the combination trials?
Merck & Co. will supply its anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
When was this announcement made?
The announcement was made on July 22, 2024.
What is the purpose of this collaboration?
The collaboration aims to further evaluate the potential of combining eftilagimod alpha with KEYTRUDA in ongoing and future clinical trials.
Filing Stats: 261 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-07-23 06:06:50
Filing Documents
- d871145d6k.htm (6-K) — 9KB
- d871145dex991.htm (EX-99.1) — 12KB
- g871145g46n03.jpg (GRAPHIC) — 4KB
- 0001193125-24-182547.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: July 22, 2024 IMMUTEP LIMITED By: /s/ Marc Voigt Name: Marc Voigt Title: Chief Executive Officer